Short-course Preoperative Chemoradiotherapy for Rectal Cancer (KROG 11-02)

October 8, 2017 updated by: Jong Hoon Lee

Two Week-course Preoperative Chemoradiotherapy Followed by Delayed Operation for Rectal Cancer: Phase II Multicenter Clinical Trial (KROG 11-02)

The purpose of this study is to evaluate the early clinical outcome of the short-course preoperative chemoradiotherapy, 33Gy/10 fx and delayed operation after chemoradiation, the investigators initiated the clinical trial of KROG 11-02.

Study Overview

Status

Unknown

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Anticipated)

80

Phase

  • Phase 2

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 75 years (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. histologically confirmed adenocarcinoma
  2. distal margin of the tumor located < 8 cm above the anal verge
  3. cT3-4 or cN+ classification as determined by endorectal ultrasonography (EUS) and CT
  4. patient older than age 18 years
  5. Karnofsky performance score >= 70

Exclusion Criteria:

  1. distant metastasis identified during staging workup
  2. previous or concurrent malignancy
  3. pregnant or breast-feeding women
  4. impending rectal obstruction
  5. familial adenomatous polyposis

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: short-course
Radiation: short-course radiation
33Gy/10 fractions

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
downstaging effect of tumor
Time Frame: an expected average of 6 weeks after chemoradiation
Comparison of clinical T staging and pathologic T staging example> cT4 --> pT1 after chemoradiation: down staging (+)
an expected average of 6 weeks after chemoradiation

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
bladder and small bowel toxicity after chemoradiation
Time Frame: Participants will be followed for an expected average of 3 months after chemoradiation
The incidence of grade 3 or higher small bowel and bladder toxicity according to the RTOG and EORTC toxicity criteria (reference: Cox JD et al. Int J Radiat Oncol Biol Phys. 1995 Mar 30;31(5):1341-6)
Participants will be followed for an expected average of 3 months after chemoradiation

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Jong Hoon Lee

Collaborators

National Cancer Center, Korea
Samsung Medical Center
Seoul National University Hospital

Investigators

  • Principal Investigator: Hong Seok Jang, MD, Department fo Radiation Oncology, Seoul St. Mary's Hospital

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

September 1, 2011

Primary Completion (Actual)

October 1, 2012

Study Completion (Anticipated)

October 1, 2017

Study Registration Dates

First Submitted

September 6, 2011

First Submitted That Met QC Criteria

September 7, 2011

First Posted (Estimate)

September 9, 2011

Study Record Updates

Last Update Posted (Actual)

October 10, 2017

Last Update Submitted That Met QC Criteria

October 8, 2017

Last Verified

October 1, 2017

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • KROG 11-02

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Rectal Cancer

Clinical Trials on short-course radiation

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Dominican Republic

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe